Mainz Biomed B.V. (MYNZ)

Market Cap	16.12M
Revenue (ttm)	895,479
Net Income (ttm)	-26.30M
Shares Out	21.89M
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,536
Open	0.791
Previous Close	0.786
Day's Range	0.720 - 0.795
52-Week Range	0.720 - 6.000
Beta	0.24
Analysts	Buy
Price Target	3.00 (+292.11%)
Earnings Date	May 14, 2024

About MYNZ

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 5, 2021
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: MYNZ

Financial Performance

In 2023, MYNZ's revenue was $895,479, an increase of 69.00% compared to the previous year's $529,877. Losses were -$26.30 million, -0.35% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for MYNZ stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 292.11% from the latest price.

Price Target

$3.0

(292.11% upside)

Analyst Consensus: Buy